Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

23andMe Holding Co. - Common Stock (NQ:ME)

0.6063 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 23andMe Holding Co. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Recap: 23andMe Holding Q3 Earnings
 
Via Benzinga
23andMe Reports Third Quarter Fiscal 2024 Financial Results
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 
From 23andMe, Inc.
Via GlobeNewswire
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
A Preview Of 23andMe Holding's Earnings
 
Via Benzinga
Why Is Invitae (NVTA) Stock Down 75% Today?
Although genetic testing specialist Invitae forwarded a compelling idea, the lack of business substance ultimately cratered NVTA stock. 
Via InvestorPlace
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures. 
Via Benzinga
Topics Bankruptcy
Troubled Biotech Company's Investigational Cancer Drug Gets Greenlighted By FDA
This development marks a significant milestone for 23andMe, a company that has been in the spotlight for security breaches in the past. 
Via Benzinga
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Faces Class Action Lawsuit Over Alleged Privacy Breach Targeting Chinese And Ashkenazi Jewish Customers
23andMe faces a class-action lawsuit for a privacy breach affecting 7 million customers, particularly Chinese and Ashkenazi Jewish customers. 
Via Benzinga
Topics Lawsuit
23andMe to Report FY2024 Third Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them
Not all of my investments have been winners. Here are three that went badly and the important lessons I learned from them. 
Via The Motley Fool
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reveals Hackers Accessed 'Significant Number' Of DNA Records
23andMe confirmed that hackers accessed around 14,000 customer accounts and an undisclosed number of files containing users' ancestry data. 
Via Benzinga
Topics Hacking
The 3 Best Digital Health Stocks for Personalized Medicine
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health. 
Via InvestorPlace
23andMe Reports Second Quarter Fiscal 2024 Financial Results
Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product margin 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
The Company’s first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
From 23andMe, Inc.
Via GlobeNewswire
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe... 
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report FY2024 Second Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END 
Via FinancialNewsMedia
The Top 7 Stocks to Own During a Downturn
Investors tend to get jittery in October but these seven stocks to own during a downturn will protect your portfolio 
Via InvestorPlace
23andMe Under Siege: Hacker Reportedly Steals Millions Of Profiles In Genetic Data Heist
An unidentified hacker reportedly claims to have stolen personal genetic data from millions of 23andMe Holding Co. (NASDAQ: ME) customer accounts, sparking concerns over privacy and security. 
Via Benzinga
Topics Hacking
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies 
From 23andMe, Inc.
Via GlobeNewswire
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
From 23andMe, Inc.
Via GlobeNewswire
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Top 5 Health Care Stocks That May Explode In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Why Olin Are Trading Lower By 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) surged 181.1% to $3.63. TradeUP Acquisition Corp. (NASDAQ: UPTD) gained 148.5% to $18.14. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.